Research | Departments
Research
Departments
Research | Departments
Research
Departments
Professor
Cancer Biology, Cancer Drug Discovery, Precision Oncology, Cancer Molecular Medicine, Cell and Molecular Biology
Laboratory of Cancer Drug Discovery
d001089012@tmu.edu.tw
Prof. Lin received his Ph.D. degree from Taipei Medical University, Taiwan, in 2007 and completed his postdoctoral training at Institute of Biological Chemistry, Academia Sinica, Taiwan , in 2014. As postdoctoral fellow, Prof. Lin worked on screening of protein targets using iodoacetamined-based probes for developing new anti-cancer drugs and identified that targeting the protein-protein interactions (PPIs) of CCT-beta/beta-tubulin (Cancer Research, 2009) and XIAP/Caspase-7 (Journal of Clinical Investigation, 2013) complexes are capable of effectively killing multidrug-resistant cancers. Then, Prof. Lin was employed as Assistance Professor in 2014 and became the Full Professor in 2021 at Graduate Institute of Clinical Medicine, Taipei Medical University.
Our laboratory is interested in identifying new biomarkers using public databases, such as The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO), for predicting the effectiveness of anti-cancer therapies, e.g. radiotherapy, chemotherapy and immunotherapy, in different cancer types. We have set up several cell-based assays to examine the irradiation/chemotherapeutic/immunotherapeutic sensitivity and cellular migration/invasion ability of tested cancer cells. We have also established orthotopic mouse models for breast cancer and oral cancer to evaluate the capacity of identified oncogenic drivers in promoting tumor growth and distant metastasis. Because genetic defects frequently result in the alteration of protein-protein interaction (PPI) network, our laboratory is also interested in discovering drug-targetable PPIs in malignancies by utilizing iodoacetamide-based probes.
1. Shang-Pen Huang, MD/Ph.D. (Co-investigator in GBM)
2. Hui-Yu Lin, MD/Ph.D. (Co-investigator in Breast Cancer)
3. Chia-Hao Kuei, MD/Ph.D. (Co-investigator in Prostate Cancer)
4. Che-Hsuan Lin, MD/Ph.D. (Co-investigator in Oral Cancer)
5. Hsun-Hua Lee, MD/Ph.D. (Co-investigator in GBM)
6. Kung-Ju Chen, Ph.D. (Postdoctoral Fellow)
7. Jing-Quan Zheng, MD (Ph.D. student focusing on Lung Cancer)
8. Wen-Ke Wang, MD (Ph.D. student focusing on Breast Cancer)
9. Yang-Sheng Lin, MD (Ph.D. student focusing on Colorectal Cancer)
10. Yiu-Shun Tong, MD (Ph.D. student focusing on Colorectal Cancer)
11. Leon Tsung-Ju Lee, MD (Ph.D. student focusing on Melanoma)
12. Kevin Shu Leung Lai, MD (Ph.D. student focusing on Lung Cancer)
13. Hsiao-Wei Lu, MD (Ph.D. student focusing on Oral Cancer)
14. Ruei-Chen Hung, MS (Ph.D. student focusing on Breast Cancer)
15. Salman Mohamed Farah, MS (Ph.D. student focusing on Breast Cancer)
16. Jui-Ping Tsai, MD (MS student)
1. Yuan TZ, Lin HY, Kuei CH, Lin CH, Lee HH, Lee HL, Lu HW, Su CY, Chiu HW, Lin YF*. NEDD8 promotes radioresistance via triggering autophagy formation and serves as a novel prognostic marker in oral squamous cell carcinoma. Cancer Cell Int. 2023 Mar 8;23(1):41.
2. Zheng JQ, Lin CH, Lee HH, Chang WM, Li LJ, Su CY, Lee KY, Chiu HW, Lin YF*. AIM2 upregulation promotes metastatic progression and PD-L1 expression in lung adenocarcinoma. Cancer Sci. 2023 Jan;114(1):306-320.
3. Kuei CH, Lin HY, Lin MH, Lee HH, Lin CH, Lee WJ, Chen YL, Lu LS, Zheng JQ, Hung RC, Chiu HW, Chen KC, Lin YF*. DNA polymerase theta repression enhances the docetaxel responsiveness in metastatic castration-resistant prostate cancer. Biochim Biophys Acta Mol Basis Dis. 2020 Dec 1;1866(12):165954.
4. Lin YF, Chou JL, Chang JS, Chiu IJ, Chiu HW, Lin YF*. Dysregulation of the miR-25-IMPA2 axis promotes metastatic progression in clear cell renal cell carcinoma. EBioMedicine. 2019 Jul;45:220-230.
5. Huang SP, Liu PY, Kuo CJ, Chen CL, Lee WJ, Tsai YH, Lin YF*. The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer. J Hematol Oncol. 2017 Jun 2;10(1):114. 3.